Coronavirus Disease 2019-Associated Pulmonary Aspergillosis

Q4 Medicine

Journal of Mycology and Infection Pub Date : 2022-03-31 DOI:10.17966/jmi.2022.27.1.1

Young-Hoon Hwang, W. Park

引用次数: 0

Abstract

As the coronavirus disease 2019 (COVID-19) pandemic continues, a new disease, COVID-19-associated pulmonary aspergillosis (CAPA), is on the rise. CAPA is a secondary fungal infection in patients with critical COVID-19 receiving mechanical ventilation in intensive care units (ICUs). Although the incidence rate of CAPA is estimated to be 10.2% in ICU patients, CAPA appears to be associated with an increase in overall mortality. CAPA is like classical invasive pulmonary aspergillosis (IPA) but has an ambiguous clinical manifestation and occurs without typical host factors. It is also like influenza-associated pulmonary aspergillosis but differs in clinical characteristics. For research and clinical practice, the European Confederation for Medical Mycology and the International Society for Human and Animal Mycology proposed novel case definition criteria for CAPA. Although CAPA management is not much different from typical IPA, areas of uncertainty remain that require further investigation.

查看原文本刊更多论文

2019冠状病毒病相关肺曲霉病

随着2019年冠状病毒病(COVID-19)大流行的持续，一种新的疾病——COVID-19相关肺曲霉病(CAPA)正在上升。CAPA是重症监护病房(icu)接受机械通气的重症COVID-19患者的继发真菌感染。虽然CAPA在ICU患者中的发病率估计为10.2%，但CAPA似乎与总死亡率的增加有关。CAPA与典型的侵袭性肺曲霉病(IPA)相似，但临床表现不明确，无典型宿主因素。它也类似于流感相关的肺曲霉病，但临床特征不同。为了研究和临床实践，欧洲医学真菌学联合会和国际人类和动物真菌学学会提出了新的CAPA病例定义标准。虽然CAPA的管理与典型的IPA没有太大的不同，但仍有不确定的领域需要进一步调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Mycology and Infection Medicine-Infectious Diseases

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： The Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods. The journal should be of general interests to the scientific communities at large and should provide medical societies with advanced breadth and depth of mycological expertise. In addition, the journal supplements infectious diseases in adjunct to the field of mycology to address a well-rounded understanding of infectious disorders. The Journal of mycology and infection, which is issued quarterly, in March, June, September and December each year, published in English. The scope of the Journal of mycology and infection includes invited reviews, original articles, case reports, letter to the editor, and images in mycology. The journal is compliant to peer-review/open access and all articles undergo rigorous reviewing processes by our internationally acknowledged team of editorial boards. The articles directed to publication should encompass in-depth materials that employ scholastic values of mycology and various infectious diseases. Articles responding to critical methodology and outcomes which have potential to enhance better understanding of mycology and infectious diseases are also suitable for publication.